Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023

Upgrades

For NVIDIA Corp NVDA, Exane BNP Paribas upgraded the previous rating of Underperform to Neutral. For the fourth quarter, NVIDIA had an EPS of $0.88, compared to year-ago quarter EPS of $1.32. The stock has a 52-week-high of $289.34 and a 52-week-low of $108.14. At the end of the last trading period, NVIDIA closed at $259.00.

For Assurant Inc AIZ, Keefe, Bruyette & Woods upgraded the previous rating of Market Perform to Outperform. Assurant earned $3.23 in the fourth quarter, compared to $2.47 in the year-ago quarter. At the moment, the stock has a 52-week-high of $194.04 and a 52-week-low of $104.49. Assurant closed at $111.19 at the end of the last trading period.

According to Tudor Pickering, the prior rating for Range Resources Corp RRC was changed from Hold to Buy. For the fourth quarter, Range Resources had an EPS of $1.30, compared to year-ago quarter EPS of $0.96. At the moment, the stock has a 52-week-high of $37.39 and a 52-week-low of $22.61. Range Resources closed at $23.33 at the end of the last trading period.

For New York Community Bancorp Inc NYCB, DA Davidson upgraded the previous rating of Hold to Buy. For the fourth quarter, New York Community had an EPS of $0.25, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of $11.28 and a 52-week-low of $5.81. At the end of the last trading period, New York Community closed at $8.61.

For Foot Locker Inc FL, Evercore ISI Group upgraded the previous rating of In-Line to Outperform. For the fourth quarter, Foot Locker had an EPS of $0.97, compared to year-ago quarter EPS of $1.67. The stock has a 52-week-high of $47.22 and a 52-week-low of $23.86. At the end of the last trading period, Foot Locker closed at $39.86.

According to Morgan Stanley, the prior rating for Harley-Davidson Inc HOG was changed from Equal-Weight to Overweight. Harley-Davidson earned $0.28 in the fourth quarter, compared to $0.15 in the year-ago quarter. The current stock performance of Harley-Davidson shows a 52-week-high of $51.77 and a 52-week-low of $29.82. Moreover, at the end of the last trading period, the closing price was at $37.55.

For Imperial Oil Ltd IMO, Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Imperial Oil earned $2.13 in the fourth quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $58.85 and a 52-week-low of $40.00. At the end of the last trading period, Imperial Oil closed at $46.60.

Piper Sandler upgraded the previous rating for Wix.com Ltd WIX from Neutral to Overweight. For the fourth quarter, Wix.com had an EPS of $0.61, compared to year-ago quarter EPS of $0.37. The current stock performance of Wix.com shows a 52-week-high of $111.33 and a 52-week-low of $53.12. Moreover, at the end of the last trading period, the closing price was at $88.38.

Piper Sandler upgraded the previous rating for Vornado Realty Trust VNO from Underweight to Neutral. Vornado Realty earned $0.72 in the fourth quarter, compared to $0.81 in the year-ago quarter. The current stock performance of Vornado Realty shows a 52-week-high of $47.11 and a 52-week-low of $13.80. Moreover, at the end of the last trading period, the closing price was at $14.38.

Raymond James upgraded the previous rating for Fleetcor Technologies Inc FLT from Market Perform to Outperform. Fleetcor Technologies earned $4.04 in the fourth quarter, compared to $3.72 in the year-ago quarter. The stock has a 52-week-high of $265.02 and a 52-week-low of $162.98. At the end of the last trading period, Fleetcor Technologies closed at $199.08.

For Foot Locker Inc FL, Citigroup upgraded the previous rating of Neutral to Buy. In the fourth quarter, Foot Locker showed an EPS of $0.97, compared to $1.67 from the year-ago quarter. The stock has a 52-week-high of $47.22 and a 52-week-low of $23.86. At the end of the last trading period, Foot Locker closed at $39.86.

Morgan Stanley upgraded the previous rating for Emerson Electric Co EMR from Equal-Weight to Overweight. Emerson Electric earned $0.78 in the first quarter, compared to $1.05 in the year-ago quarter. At the moment, the stock has a 52-week-high of $99.99 and a 52-week-low of $72.42. Emerson Electric closed at $82.27 at the end of the last trading period.

According to Telsey Advisory Group, the prior rating for Foot Locker Inc FL was changed from Market Perform to Outperform. In the fourth quarter, Foot Locker showed an EPS of $0.97, compared to $1.67 from the year-ago quarter. The current stock performance of Foot Locker shows a 52-week-high of $47.22 and a 52-week-low of $23.86. Moreover, at the end of the last trading period, the closing price was at $39.86.

According to Morgan Stanley, the prior rating for Meta Platforms Inc META was changed from Equal-Weight to Overweight. Meta Platforms earned $1.76 in the fourth quarter, compared to $3.67 in the year-ago quarter. The current stock performance of Meta Platforms shows a 52-week-high of $205.76 and a 52-week-low of $88.10. Moreover, at the end of the last trading period, the closing price was at $197.81.

See all analyst ratings upgrades.

Downgrades

For Armstrong World Industries Inc AWI, Deutsche Bank downgraded the previous rating of Buy to Hold. For the fourth quarter, Armstrong World Indus had an EPS of $1.08, compared to year-ago quarter EPS of $1.09. The stock has a 52-week-high of $96.51 and a 52-week-low of $67.14. At the end of the last trading period, Armstrong World Indus closed at $69.45.

According to Maxim Group, the prior rating for Cyclo Therapeutics Inc CYTH was changed from Buy to Hold. Cyclo Therapeutics earned $0.59 in the fourth quarter, compared to $0.34 in the year-ago quarter. The current stock performance of Cyclo Therapeutics shows a 52-week-high of $3.35 and a 52-week-low of $0.86. Moreover, at the end of the last trading period, the closing price was at $0.94.

For ORIC Pharmaceuticals Inc ORIC, Guggenheim downgraded the previous rating of Buy to Neutral. For the fourth quarter, ORIC Pharmaceuticals had an EPS of $0.52, compared to year-ago quarter EPS of $0.58. The stock has a 52-week-high of $7.45 and a 52-week-low of $2.37. At the end of the last trading period, ORIC Pharmaceuticals closed at $4.49.

Ladenburg Thalmann downgraded the previous rating for Athenex Inc ATNX from Buy to Neutral. Athenex earned $4.28 in the fourth quarter, compared to $6.40 in the year-ago quarter. The current stock performance of Athenex shows a 52-week-high of $24.00 and a 52-week-low of $1.24. Moreover, at the end of the last trading period, the closing price was at $1.26.

Scotiabank downgraded the previous rating for Suncor Energy Inc SU from Sector Outperform to Sector Perform. In the fourth quarter, Suncor Energy showed an EPS of $1.35, compared to $0.71 from the year-ago quarter. The stock has a 52-week-high of $42.71 and a 52-week-low of $26.44. At the end of the last trading period, Suncor Energy closed at $29.72.

Piper Sandler downgraded the previous rating for GoDaddy Inc GDDY from Overweight to Neutral. In the fourth quarter, GoDaddy showed an EPS of $0.60, compared to $0.52 from the year-ago quarter. The current stock performance of GoDaddy shows a 52-week-high of $88.30 and a 52-week-low of $64.69. Moreover, at the end of the last trading period, the closing price was at $74.40.

Jefferies downgraded the previous rating for Profound Medical Corp PROF from Buy to Equal-Weight. For the fourth quarter, Profound Medical had an EPS of $0.46, compared to year-ago quarter EPS of $0.49. At the moment, the stock has a 52-week-high of $13.52 and a 52-week-low of $3.10. Profound Medical closed at $10.16 at the end of the last trading period.

For Agree Realty Corp ADC, JMP Securities downgraded the previous rating of Market Outperform to Market Perform. For the fourth quarter, Agree Realty had an EPS of $0.95, compared to year-ago quarter EPS of $0.91. The current stock performance of Agree Realty shows a 52-week-high of $80.41 and a 52-week-low of $63.34. Moreover, at the end of the last trading period, the closing price was at $68.84.

According to Wolfe Research, the prior rating for Oak Street Health Inc OSH was changed from Outperform to Peer Perform. In the fourth quarter, Oak Street Health showed an EPS of $0.56, compared to $0.62 from the year-ago quarter. The stock has a 52-week-high of $35.84 and a 52-week-low of $13.35. At the end of the last trading period, Oak Street Health closed at $35.70.

Stifel downgraded the previous rating for Electrameccanica Vehicles Corp Ltd SOLO from Buy to Hold. In the third quarter, Electrameccanica Vehicles showed an EPS of $0.18, compared to $0.11 from the year-ago quarter. The stock has a 52-week-high of $2.44 and a 52-week-low of $0.57. At the end of the last trading period, Electrameccanica Vehicles closed at $0.58.

See all analyst ratings downgrades.

Initiations

SVB Leerink initiated coverage on Rain Oncology Inc RAIN with an Outperform rating. The price target for Rain Oncology is set to $11.00. For the fourth quarter, Rain Oncology had an EPS of $0.70, compared to year-ago quarter EPS of $0.68. The stock has a 52-week-high of $14.48 and a 52-week-low of $2.18. At the end of the last trading period, Rain Oncology closed at $7.77.

Bernstein initiated coverage on Vertex Pharmaceuticals Inc VRTX with an Outperform rating. The price target for Vertex Pharmaceuticals is set to $344.00. Vertex Pharmaceuticals earned $3.76 in the fourth quarter, compared to $3.37 in the year-ago quarter. At the moment, the stock has a 52-week-high of $325.19 and a 52-week-low of $233.14. Vertex Pharmaceuticals closed at $298.95 at the end of the last trading period.

With an Underperform rating, Bernstein initiated coverage on Biomarin Pharmaceutical Inc BMRN. The price target seems to have been set at $81.00 for Biomarin Pharmaceutical. In the fourth quarter, Biomarin Pharmaceutical showed an EPS of $0.00, compared to $0.32 from the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $117.77 and a 52-week-low of $70.76. Moreover, at the end of the last trading period, the closing price was at $92.34.

Bernstein initiated coverage on Alnylam Pharmaceuticals Inc ALNY with an Outperform rating. The price target for Alnylam Pharmaceuticals is set to $243.00. Alnylam Pharmaceuticals earned $1.39 in the fourth quarter, compared to $1.74 in the year-ago quarter. The stock has a 52-week-high of $242.74 and a 52-week-low of $117.62. At the end of the last trading period, Alnylam Pharmaceuticals closed at $187.52.

With an Outperform rating, Bernstein initiated coverage on Intellia Therapeutics Inc NTLA. The price target seems to have been set at $54.00 for Intellia Therapeutics. For the fourth quarter, Intellia Therapeutics had an EPS of $1.40, compared to year-ago quarter EPS of $1.09. At the moment, the stock has a 52-week-high of $78.58 and a 52-week-low of $32.44. Intellia Therapeutics closed at $38.27 at the end of the last trading period.

Bernstein initiated coverage on Beam Therapeutics Inc BEAM with a Market Perform rating. The price target for Beam Therapeutics is set to $37.00. Beam Therapeutics earned $0.54 in the fourth quarter, compared to $0.95 in the year-ago quarter. The current stock performance of Beam Therapeutics shows a 52-week-high of $73.26 and a 52-week-low of $27.90. Moreover, at the end of the last trading period, the closing price was at $32.23.

With a Market Perform rating, Bernstein initiated coverage on Allogene Therapeutics Inc ALLO. The price target seems to have been set at $6.00 for Allogene Therapeutics. For the fourth quarter, Allogene Therapeutics had an EPS of $0.66, compared to year-ago quarter EPS of $0.54. At the moment, the stock has a 52-week-high of $17.48 and a 52-week-low of $5.27. Allogene Therapeutics closed at $5.37 at the end of the last trading period.

Bernstein initiated coverage on CRISPR Therapeutics AG CRSP with a Market Perform rating. The price target for CRISPR Therapeutics is set to $44.00. CRISPR Therapeutics earned $1.41 in the fourth quarter, compared to $1.84 in the year-ago quarter. The stock has a 52-week-high of $86.79 and a 52-week-low of $38.94. At the end of the last trading period, CRISPR Therapeutics closed at $44.46.

Bernstein initiated coverage on Arrowhead Pharmaceuticals Inc ARWR with a Market Perform rating. The price target for Arrowhead Pharma is set to $27.00. Arrowhead Pharma earned $0.39 in the first quarter, compared to $0.60 in the year-ago quarter. The stock has a 52-week-high of $51.01 and a 52-week-low of $23.09. At the end of the last trading period, Arrowhead Pharma closed at $25.06.

With an Underperform rating, Bernstein initiated coverage on Ionis Pharmaceuticals Inc IONS. The price target seems to have been set at $31.00 for Ionis Pharmaceuticals. For the fourth quarter, Ionis Pharmaceuticals had an EPS of $1.18, compared to year-ago quarter EPS of $1.55. The stock has a 52-week-high of $48.82 and a 52-week-low of $31.46. At the end of the last trading period, Ionis Pharmaceuticals closed at $35.60.

Wells Fargo initiated coverage on Ventyx Biosciences Inc VTYX with an Overweight rating. The price target for Ventyx Biosciences is set to $77.00. Ventyx Biosciences earned $0.59 in the third quarter, compared to $3.17 in the year-ago quarter. The current stock performance of Ventyx Biosciences shows a 52-week-high of $47.25 and a 52-week-low of $9.96. Moreover, at the end of the last trading period, the closing price was at $37.85.

See all analyst ratings initiations.